source
- Novo abandons $285 million partnership with Ascendis for monthly GLP-1 obesity drugNovo Nordisk, which recently rebranded, has terminated a licensing agreement with Ascendis Pharma that was originally valued at up to $285 million. The collaboration, signed in November 2024, was…
- FDA issues warning letters to Bausch & Lomb and Indian API maker over GMP lapsesThe U.S. Food and Drug Administration sent warning letters to two companies after finding violations of good manufacturing practice. Bausch & Lomb, which produces ophthalmic products, was cited f…